Rapid Chlamydia Testing

Building a test that addresses the real-world challenges of reducing the spread of sexually transmitted infections (STIs)

A Pressing Public Health Challenge


Chlamydia trachomatis is the most frequently reported bacterial infection in the United States, with infection rates continuing to increase across all regions, ethnic groups, and genders.1 However, many cases are asymptomatic and undiagnosed, leading to a likely underestimate of the true disease prevalence.2 Underdiagnosis has a direct impact on women’s health, as untreated Chlamydia infection can lead to painful pelvic inflammatory disease and infertility.



Cases of Chlamydia reported in 2019 in the US1



Of these cases were in people aged 15 – 241



Of women and 40-50% of men infected with Chlamydia are asymptomatic2

A Clear Need for Rapid Chlamydia Testing


The asymptomatic nature of Chlamydia further complicates management of the disease. Nucleic acid amplification tests (NAAT) are the current gold standard, but most NAATs for Chlamydia must be performed in a central lab, requiring patients to return to their health care provider for treatment should the results be positive.3 Several studies have shown that 20% or more of patients with positive STI tests fail to return for treatment.3 The lack of immediate symptoms and the stigma associated with STIs may explain, in part, the reluctance of patients to return for a second visit. Additional barriers to return visits may be due to difficulties obtaining time off from work an/or finding transportation to the clinic.

Diagnostic tests that could be performed at the point of care and provide results within minutes could help ensure more patients with Chlamydia infections receive treatment, potentially interrupting the transmission cycle.

“If an infected patient receives timely treatment at an initial visit, further transmission can be interrupted.”

-Barrow, et al.3

Talis One™: The Next Big Thing in Rapid Chlamydia Testing


Designed to help maximize health outcomes in the face of infectious diseases like Chlamydia, the Talis One Instrument may enable fast, accurate, lab-quality molecular diagnostic testing in a variety of care settings.

We have already developed a Talis One COVID-19 Test System that was granted an Emergency Use Authorization (EUA) in the second half of 2021. We are now developing a Talis One Chlamydia Test System that is designed to bring rapid chlamydia testing to sexually transmitted disease (STD) clinics, urgent care clinics, and primary care offices.

Talis One Point-of-care Instrument


The Talis One point-of-care instrument delivers rapid, reliable, and accurate, lab-quality diagnostic testing results across a variety of CLIA-waived care settings.

Talis One Consumables


The Talis One Nasal Mid-Turbinate Collection Kit stabilizes viral RNA and inactivates viruses.1 Each single-use cartridge contains a highly sensitive, solid-phase nucleic acid amplification test (NAAT). 

Dedicated Talis One Customer Support


Our Customer Service support team is happy to help answer your questions.

The Talis One system is poised to help you break the cycle of transmission of STIs. Tell us what capabilities you’d like to see in a point-of-care Chlamydia test.

Get In Touch

Join Our Newsletter

Subscribe to our newsletter for information about our products and company updates.


    The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

    © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

    *Additional testing solutions are currently in development and not available for sale.


    1. National Overview – Sexually Transmitted Disease Surveillance, 2019. Centers for Disease Control and Prevention. Published April 2021. Accessed July 29, 2021.
    2. Shetty S, et al. Diagnosis of Chlamydia trachomatis genital infections in the era of genomic medicine. Braz J Microbiol. 2021 Jun 23;1-13. PMCID: PMC8221097
    3. Barrow RY, et al. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep. 2020 Jan 3;68(5):1-20. PMCID: PMC6950496